|1.||Bennouna, J: 5 articles (02/2014 - 04/2003)|
|2.||Kruczynski, Anna: 5 articles (01/2013 - 09/2004)|
|3.||Bellmunt, Joaquim: 5 articles (07/2012 - 06/2008)|
|4.||Campone, M: 4 articles (05/2014 - 04/2003)|
|5.||Fumoleau, P: 4 articles (06/2013 - 04/2003)|
|6.||Pinel, M C: 4 articles (06/2013 - 09/2006)|
|7.||Pinel, Marie-Claire: 4 articles (02/2013 - 05/2006)|
|8.||Fougeray, Ronan: 4 articles (02/2013 - 04/2010)|
|9.||Braguer, Diane: 4 articles (01/2013 - 09/2004)|
|10.||Salhi, Yacine: 4 articles (07/2012 - 09/2009)|
|1.||Breast Neoplasms (Breast Cancer)
11/06/2006 - "Vinflunine: a new active drug for second-line treatment of advanced breast cancer. "
03/15/2008 - "Vinflunine is currently in phase III trial assessment in patients with (second line) transitional cell carcinoma of the urothelium and first-line advanced breast cancer. "
05/01/2014 - "A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer."
06/01/2011 - "A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer."
11/01/2010 - "A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer."
01/01/2016 - "Vinflunine appears to be a safe and effective treatment modality for relapsed urothelial cancer. "
03/01/2014 - "How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study."
01/01/2014 - "The objective of this prospective observational study was to assess vinflunine treatment of advanced urothelial cancer patients in terms of progression free survival and overall survival, and to evaluate vinflunine toxicity. "
01/01/2014 - "Based on the results of phase III trial, vinflunine was approved by European Medicines Agency in 2010 as second line treatment of advanced urothelial cancer in patients with good performance status (ECOG 0- 1). "
01/01/2014 - "This retrospective study confirms that the clinical outcomes obtained from routine medical practice in Germany with vinflunine in the treatment of advanced/metastatic urothelial cancer are in line with the data observed in prior clinical trials."
|3.||Transitional Cell Carcinoma
05/22/2006 - "A multicentre phase II trial to determine the efficacy of vinflunine as second-line therapy in patients with advanced transitional cell carcinoma (TCC) of the bladder; secondary objectives were to assess duration of response, progression-free survival (PFS) and overall survival (OS), and to evaluate the toxicity associated with this treatment. "
06/01/2013 - "The first report (Bellmunt J, Theodore C, Demkov T et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinumcontaining regimen in patients with advanced transitional cell carcinoma of the urothelial tract. "
09/01/2015 - "Effectiveness, toxicity, and economic evaluation of vinflunine for the treatment of patients with transitional cell carcinoma in the Spanish outpatient setting."
11/01/2013 - "Vinflunine is also a new synthetic vinca alkaloid, which has been approved in Europe for the treatment of second-line transitional cell carcinoma of the urothelium is being developed for other malignancies. "
09/20/2009 - "Vinflunine (VFL) is a new microtubule inhibitor that has activity against transitional cell carcinoma of urothelial tract (TCCU). "
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/22/2006 - "The encouraging results from this phase II study with vinflunine warrant further investigations in phase III trials as second- or first-line treatment of advanced non-small-cell lung carcinoma, as a single agent or in combination with other active drugs."
08/01/2012 - "Vinflunine (VFL) (Javlor(®)), a novel fluorinated semisynthetic vinca alkaloid has shown significant antitumor activity in advanced non-small cell lung cancer (NSCLC). "
10/01/2011 - "Vinflunine for non-small cell lung cancer: realistic hopes?"
07/01/2011 - "Vinflunine (Javlor) has shown significant antitumour activity in advanced non-small cell lung cancer (NSCLC). "
03/15/2008 - "The efficacy of vinflunine in patients with advanced non-small cell lung cancer previously treated with a platinum-containing regimen was confirmed by a large phase III trial."
06/01/2015 - "[Activity and efficacy of vinflunine in metastatic carcinoma of the bladder after failure of adjuvant treatment: description of a clinical case]."
01/01/2011 - "This review gives a brief outline on vinflunine as a second-line treatment for platin-resistant advanced urothelial carcinoma; it describes pharmacology, efficacy studies, tolerance, and side effects and briefly discusses future clinical perspectives."
01/01/2015 - "Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience."
01/01/2014 - "The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas."
04/01/2013 - "Urothelial carcinoma: vinflunine offers modest but important survival benefit."
|3.||erlotinib (CP 358,774)
|4.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|9.||Vinblastine (Vinblastine Sulfate)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)